Rip biological porcine circovirus vaccine is expected to be available in the second quarter

The head of rip biology told reporters yesterday that porcine circovirus type 2 (PCV2) is one of the three major viral infectious diseases emerging in recent years, which has brought serious economic losses to the pig industry The company has also been strengthening research and development and investment in this area On February 20, rip bio announced that the inactivated vaccine of porcine circovirus type 2 (ZJ / C strain) declared by RIP bio Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, was approved as a class III new veterinary drug by the Ministry of agriculture of China On February 8, 2013, Rip (Baoding) bio Pharmaceutical Co., Ltd received the new veterinary drug registration certificate issued by the Ministry of agriculture The person in charge of the company told reporters that the company has obtained the registration certificate and the official approval has not yet been issued It is expected to receive the approval in April, "if all goes well, the inactivated vaccine of porcine circovirus type 2 will be available for sale in the second quarter of this year." According to the reporter, rip bio began to research and develop the vaccine related to porcine circovirus in 2006 At present, it has a number of technical reserves Last year and this year, new production equipment was purchased, and there is no obstacle to production capacity In the first quarter of 2013, rip bio continued to push forward the strategic landing, continued to deepen and consolidate strategic cooperation with key customers in the market, and actively promoted the construction of southwest and South China markets The first quarter performance forecast shows that the first quarter will achieve a profit of 27.19 million yuan to 29.66 million yuan, an increase of about 10% to 20% over the same period last year.